Legal & General Group Plc - HALOZYME THERAPEUTICS INC ownership

HALOZYME THERAPEUTICS INC's ticker is HALO and the CUSIP is 40637H109. A total of 216 filers reported holding HALOZYME THERAPEUTICS INC in Q3 2019. The put-call ratio across all filers is 0.44 and the average weighting 0.2%.

Quarter-by-quarter ownership
Legal & General Group Plc ownership history of HALOZYME THERAPEUTICS INC
ValueSharesWeighting
Q3 2023$9,011,573
+2.9%
235,905
-2.9%
0.00%0.0%
Q2 2023$8,759,490
-19.5%
242,847
-14.8%
0.00%
-25.0%
Q1 2023$10,880,063
-19.7%
284,893
+19.6%
0.00%
-20.0%
Q4 2022$13,555,290
+44.1%
238,230
+0.1%
0.01%
+25.0%
Q3 2022$9,409,000
-21.4%
237,959
-12.6%
0.00%0.0%
Q2 2022$11,973,000
+2.9%
272,125
-6.7%
0.00%0.0%
Q1 2022$11,636,000
-2.0%
291,756
-1.2%
0.00%0.0%
Q4 2021$11,876,000
-1.0%
295,353
+0.2%
0.00%0.0%
Q3 2021$11,991,000
+2.2%
294,767
+14.1%
0.00%0.0%
Q2 2021$11,729,000
+27.1%
258,298
+16.7%
0.00%
+33.3%
Q1 2021$9,226,000
-2.7%
221,294
-0.3%
0.00%
-25.0%
Q4 2020$9,479,000
+229.1%
221,958
+102.6%
0.00%
+300.0%
Q3 2020$2,880,000
-11.7%
109,569
-9.9%
0.00%
-50.0%
Q2 2020$3,261,000
+77.6%
121,656
+19.0%
0.00%
+100.0%
Q1 2020$1,836,000
-9.1%
102,245
-10.2%
0.00%0.0%
Q4 2019$2,019,000
+42.2%
113,822
+24.2%
0.00%0.0%
Q3 2019$1,420,000
+19.6%
91,624
+32.6%
0.00%0.0%
Q2 2019$1,187,000
+34.3%
69,093
+25.8%
0.00%0.0%
Q1 2019$884,000
-12.1%
54,941
-20.0%
0.00%0.0%
Q4 2018$1,006,000
+0.7%
68,707
+25.0%
0.00%0.0%
Q3 2018$999,000
+38.0%
54,981
+28.1%
0.00%0.0%
Q2 2018$724,000
-17.6%
42,937
-4.3%
0.00%0.0%
Q1 2018$879,000
-27.1%
44,878
-24.3%
0.00%0.0%
Q4 2017$1,205,000
+15.3%
59,289
-1.4%
0.00%0.0%
Q3 2017$1,045,000
+84.3%
60,157
+36.4%
0.00%
Q2 2017$567,000
+13.6%
44,116
+14.5%
0.00%
Q1 2017$499,000
+29.3%
38,531
-1.2%
0.00%
Q4 2016$386,000
+21.4%
39,011
+46.0%
0.00%
Q3 2016$318,000
+37.1%
26,714
-2.3%
0.00%
Q2 2016$232,000
-11.1%
27,3320.0%0.00%
Q1 2016$261,000
-31.1%
27,332
+24.6%
0.00%
Q4 2015$379,000
+37.3%
21,940
+6.1%
0.00%
Q3 2015$276,000
-39.5%
20,6830.0%0.00%
-100.0%
Q2 2015$456,000
+55.6%
20,6830.0%0.00%
Q1 2015$293,000
+91.5%
20,683
+30.5%
0.00%
Q4 2014$153,000
+4.1%
15,8530.0%0.00%
Q3 2014$147,00015,8530.00%
Other shareholders
HALOZYME THERAPEUTICS INC shareholders Q3 2019
NameSharesValueWeighting ↓
TRAN CAPITAL MANAGEMENT, L.P. 1,084,118$61,686,2857.80%
SNYDER CAPITAL MANAGEMENT L P 3,983,814$226,679,0175.12%
First Light Asset Management, LLC 923,119$52,525,4714.88%
Redwood Investments, LLC 441,809$25,138,9323.37%
BERNZOTT CAPITAL ADVISORS 444,728$25,305,0233.27%
DOHENY ASSET MANAGEMENT /CA 46,050$2,6203.04%
Crawford Lake Capital Management, LLC 42,171$2,399,5302.75%
2Xideas AG 416,586$23,703,7432.51%
Granite Investment Partners, LLC 902,882$51,373,9862.14%
HighMark Wealth Management LLC 41,790$2,377,8511.79%
View complete list of HALOZYME THERAPEUTICS INC shareholders